Atomwise, which uses artificial intelligence for structure-based small molecule drug discovery, has raised $123 million in an oversubscribed Series B round, according to a company statement on Tuesday. The San Francisco-based firm said it will use the proceeds to scale and build its own pipeline of experimental drugs.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in